ArticlePDF Available

Heat-stable antigen is a costimulatory molecule for CD4 T cell growth

Rockefeller University Press
Journal of Experimental Medicine (JEM)
Authors:

Abstract

Optimal induction of clonal expansion by normal CD4 T cells requires a ligand that can engage the T cell receptor as well as functionally defined costimulatory activity on the same antigen-presenting cell surface. While the presence of effective costimulation induces proliferation, T cell receptor ligation in its absence renders T cells inactive or anergic. The molecular basis of this costimulatory activity remains to be defined. Here we describe a monoclonal antibody that can block the costimulatory activity of splenic accessory cells. Treatment with this antibody not only blocks the proliferation of CD4 T cells to a T cell receptor ligand, but also induces T cell nonresponsiveness to subsequent stimulation. Sequence analysis of the antigen recognized by this antibody indicates that it recognizes a protein that is identical to heat-stable antigen. Gene transfer experiments directly demonstrate that this protein has costimulatory activity. Thus, heat-stable antigen meets the criteria for a costimulator of T cell clonal expansion.
Heat-stable Antigen Is a Costimulatory Molecule for
CD4 T Cell Growth
By Yang Liu,* Bryan Jones,$ Alejandro Aruffo, S Kate M. Sullivan,*
Peter S. Linsley,$ and Charles A. Janeway, Jr.*~
From the "Section of Immunobiology, Yale University School of Medicine, and SHoward Hughes
Medical Institute, New Haven, Connecticut 06510; and SBristol-Myers Squibb Pharmaceutical
Research Institute, Seattle, Washington 98121
Summary
Optimal induction of clonal expansion by normal CD4 T cells requires a ligand that can engage
the T cell receptor as well as functionally defined costimulatory activity on the same antigen-
presenting cell surface. While the presence of effective costimulation induces proliferation, T
cell receptor ligation in its absence renders T cells inactive or anergic. The molecular basis of
this costimulatory activity remains to be defined. Here we describe a monoclonal antibody that
can block the costimulatory activity of splenic accessory cells. Treatment with this antibody not
only blocks the proliferation of CD4 T cells to a T cell receptor ligand, but also induces T
cell nonresponsiveness to subsequent stimulation. Sequence analysis of the antigen recognized
by this antibody indicates that it recognizes a protein that is identical to heat-stable antigen.
Gene transfer experiments directly demonstrate that this protein has costimulatory activity. Thus,
heat-stable antigen meets the criteria for a costimulator of T cell clonal expansion.
O
ne of the most prominent features of the adaptive im-
mune system is the generation of diversity by random
somatic gene rearrangement (1). The generation of diversity
provides the receptors needed to recognize novel pathogens.
However, this diversity creates two problems for the immune
system. The first problem is self-nonself discrimination. Be-
cause the repertoire of receptors is somatically generated, each
clone has to be tested for self-reactivity, and autoreactive clones
have to be inactivated or eliminated. The second problem
is the low frequency of specific lymphocytes. As the frequency
of any specific clone is the reciprocal of the diversity of
receptors, the adaptive immune response requires clonal ex-
pansion of specific lymphocytes. This requirement for clonal
expansion in adaptive immunity (including autoimmune re-
sponses) provides the immune system with a crucial control
point at which these two problems may be solved.
Many recent experiments have demonstrated that the clonal
expansion of all lymphocytes requires both receptor ligation
and the receipt of a poorly defined costimulatory signal(s).
In the case ofT cells, clonal expansion requires both a specific
peptide/MHC ligand and costimulatory activity on APCs.
Early work from Lafferty et al. (2, 3) indicted that treatment
of APCs with UV light or heat inactivation could destroy
the immunogenicity of the APC without affecting its anti-
genicity. They referred to the activity being destroyed as
"costimulatory activity" Most importantly, they showed that
this activity is intrinsic to cells of hemopoietic origin, as deple-
tion of hemopoietic cells from allografts leads to acceptance
of the graft and a gradual induction of immune tolerance.
More recently, Schwartz and coworkers (4, 5) have used a
well-defined tissue culture model to demonstrate that fixa-
tion of APCs leads to clonal anergy in the presence of specific
peptides. Such treatment does not affect the generation of
the TCR ligand, so it is postulated that clonal anergy is in-
duced by engaging the TCK in the absence of costimula-
tion. More recently, we have demonstrated that engaging the
TCR of cloned Thl cells in the absence of a costimulatory
signal leads to the death of Thl effector cells (6). Finally,
the finding that stimulation of T cells with the TCR ligand
alone leads to clonal anergy has been confirmed in transgenic
mice that express MHC antigens on nonhemopoietic tissues
such as B cells of the islets of Langerhans (7, 8). Together,
these studies demonstrate that costimulatory activity on APCs
plays a key role in determining the consequences of the inter-
action of the TCR with its ligand. It is therefore of great
interest to define molecules on APC that are involved in
costimulation of T cells.
Clonal expansion of T cells involves the binding of the
TCR and its coreceptors to a peptide/MHC ligand, mAbs
to a variety of other T cell and APC molecules have been
shown to inhibit T cell proliferation, including lymphocyte
function-associated molecule 1/intracellular adhesion mole-
cule 1 (LFA-1/ICAM-1) (9), CD2/LFA3 (10), and CD28/
B7BB1 (11-13). Although all of these receptor/ligand pairs
would be defined as costimulatory, we prefer to divide these
interactions into two distinguishable sets. mAbs to one set
437 J. Exp. Med. 9 The Rockefeller University Press 9
0022-1007/92/02/0437/09
$2.00
Volume 175 February 1992 437--445
on July 10, 2011jem.rupress.orgDownloaded from
Published February 1, 1992
of molecules disrupts T cell responses even in situations where
clonal expansion is not critical, as in target cell recognition
by killer T cells. Molecules of this class are involved in an-
tigen recognition by the T cell. mAbs to the other set affect
only clonal expansion. These recognize what we would call
costimulators, as they regulate T cell behavior after an an-
tigen is recognized. In the presence ofmAbs to such costimula-
tory molecules, not only would clonal expansion be blocked,
but also one would expect a state of T cell inactivation or
anergy to be induced. By contrast, mAbs that prevent TCR
signaling should prevent the induction of anergy. This pro-
vides a test for distinguishing between the two sets of mAbs
that prevent T cell clonal expansion.
In this report, we describe a mAb, 20C9, that blocks clonal
expansion of normal CD4 T cells. Engagement of the TCR
in the presence of this mAh leads to functional inactivation
of T cells. Thus, this mAb meets the criteria for inhibition
of the delivery of costimulatory activity by APCs. Expres-
sion cloning and cDNA sequencing reveal that this mAb recog-
nizes the heat-stable antigen. Gene transfer experiments
confirm that heat-stable antigen has a direct costimulatory
activity for clonal expansion of normal CD4 T cells.
Materials and Methods
Production ofmAbs. BALB/c
ByJ and CBA/CaJ mice, used at
8-10 wk old, were purchased from The Jackson Laboratory (Bar
Harbor, ME). Armenian hamsters (Cytogen Research and Devel-
opment, West Roxbury, MA) were immunized by four consecu-
tive intraperitoneal injections each of 107 LPS-activated B cells
from CBA/CaJ mice. The spleen cells were fused to Ag8.653 and
hybrids selected in HAT medium. The supernatants were screened
for their ability to inhibit the proliferation of CD4 T cells purified
from BALB/cByJ mice to the anti-CD3 mAb YCD3-1 (14) and
irradiated LPS-activated syngeneic B cells as described (15). Posi-
tive clones were subcloned three times, mAbs were purified from
hybridoma supernatants on a protein G--Sepharose column.
Expression Cloning of 20C9 cDNA and Generation of CHO Trans-
fectants.
20C9 cDNA was cloned as previously described (16).
Briefly, a cDNA library was prepared from mKNA isolated from
LPS- and IL-4-activated BALB/c spleen ceils and inserted into the
pCDM8 expression vector. The cDNA library was transfected into
COS cells by the DEAE-dextran method (16), COS cells were in-
cubated with 20C9 mAb, and the cells expressing 20C9 protein
were isolated by panning onto plates coated with goat anti-ham-
ster IgG (Caltag Laboratories, San Francisco, CA). Episomal DNA
was recovered from the adherent cells, amplified in
Escherichia coli,
and reintroduced into COS cells. After three rounds of transfec-
tion and panning, plasmid DNA was prepared from individual bac-
terial colonies and transfected into COS cells. The cell surface
expression of 20C9 protein was determined by indirect immuno-
fluorescence.
cDNA from clone 20C9C7 was transfected into CHO cells that
had previously been transfected with the gene encoding FcKIIB2
(kind gift of Dr. Ira Mellman, Yale University; 17), according to
previously described procedures (11). Briefly, a mixture of 10 #g
of 20C9C7 DNA and 1 #g of EBOpLPP vector carrying a
hygromycin-resistance gene was used to transfect COS cells by
lipofection. These ceils were then selected with DMEM containing
0.4 mg/ml of hygromycin and 5% FCS. Positive cells were sorted
2 wk later in a FACStar Plus | cell sorter (Becton Dickinson &
Co.), and individual clones were obtained by limiting dilution.
438
Assays for Proliferation of CD4 T Cells.
Both normal CD4 T
cells and cloned Thl ceils were used in this study. Normal CD4
T cells were prepared from CBA/CaJ and BALB/cByJ mice as de-
scribed (15). The Thl clone 5.9 has also been described fully (18).
B ceUs were prepared from spleen nonadherent ceils after two rounds
of anti-Thy-1 mAb (HO 13.4.9; reference 19) and complement lysis,
and were activated with 10 ~tg/ml of LPS (15). These B cells were
either irradiated (2,000 rad) or fixed with 1% paraformaldehyde
(15) before being used as accessory cells. In some experiments, acti-
vated B ceUs (107/ml) were incubated with 100 #g/ml of mAb for
i h at 4~ before fixation. Transfectants of CHO cells were treated
with mitomycin C (100 #g/ml) before use as accessory cells. Un-
less specified in the text, CD4 T cells were purified as previously
described and incubated with accessory cells and a 1:40 dilution
of YCD3-1. Proliferation was determined after 42 h by pulsing the
culture for 6 h with 1 #Ci/well of [~H]TdR. Results of dupli-
cate/triplicate cultures in which the variation was g20% are
reported.
Cleavage of Glffosyl-Phosphatidylinositol (GPI)' Linkage by
Phosphoinositol-s~cific Phospholipase C (PI-PLC) and Flow Cytometry.
A20 cells (10Vml) in serum-free Click's EHAA medium were in-
cubated with PI-PLC (152354; ICN Biochemicals, Cleveland, OH),
at a 1:200 dilution at 37~ in a water bath for 1 h. The enzyme
was washed away with PBS, and the treated and untreated cells
were stained with 20C9 mAb undiluted hybridoma supernatant
followed by FITC-labeled goat anti-hamster IgG (mouse and rat
Ig adsorbed; Cahag Laboratories). Anti-Mac-1 mAb M1/70 (20),
anti-FcR mAb 2.4G2 (21), and anti-heat-stable antigen mAbs Jlld
(22) and M1/69 (23) were also used in flow cytometry and/
or proliferation assays, which was performed as described pre-
viously (15).
Results
A mAb that Inhibits T Cell Clonal Expansion by Blocking
the Delivery of Costimulatory Activity by APC.
To study the
clonal expansion of normal CD4 T cells, we have used anti-
CD3 mAb-induced proliferation of CD4 T cells as a model
system. Our previous work has demonstrated that B cells
are the major APC for this response in murine spleen (15).
Activation with LPS induces costimulatory activity in B cells
that is resistant to aldehyde fixation. To generate mAbs that
can block the delivery of this costimulatory signal for T cell
activation, we immunized hamsters with LPS-activated B cells
and made hybridomas. Supematants were screened for inhibi-
tory effects on the proliferation of normal CD4 T cells to
anti-CD3 mAb and irradiated, LPS-activated B cells as acces-
sory cells. The hybridomas that secreted inhibitory mAbs were
subcloned three times. One of these inhibitory rnAbs, 20C9,
is characterized here. 20C9 significantly inhibits the prolifer-
ation of CD4 T calls induced by anti-CD3 (Fig. 1 a) or by
allogeneic LPS-activated B calls (Fig. 1 b). When a cloned
T cell is used as a responder, 20C9 blocks proliferation of
this cloned line to its antigen, OVA (Fig. 1 c). 20C9 also
inhibits proliferation of total spleen cells to anti-CD3 (see
Fig. 3 a), indicating that the antibody has a broad spectrum
1 Abbreviations used in this paper:
GPI, glycosyl-phosphatidylinositol; PI-
PLC, phosphoinosltol-specific phospholipase C.
Heat-stable Antigen Is a Costimulator of T Cell Clonal Expansion
on July 10, 2011jem.rupress.orgDownloaded from
Published February 1, 1992
E
D,.
0
20C9
103 ......
, ....... . .......
10 0 101 10 2 10 3
10 s
1/Dilution
80000'
60000 '
40000
20000
0'
1
80000"
60000-
40OOO
~, 20000-
"% 0
4 1 0 s 1 0 e
Accessory cells
Med 20C9
Figure 1. mAb 20C9 inhibits proliferation of T cells.
(a) Proliferation of CD4 T cells to anti-CD3. BALB/c CD4
T cells (5 x 104/we11) were cultured with 2 x 104 ir-
radiated, LPS-activated B cells in the presence of anti-CD3
mAb (YCD3-1, hybridoma supernatant; 1:40). Varying
concentrations of 20C9 supernatant were added at the be-
ginning of the culture. (b) Proliferation ofBALB/ByJ CD4
T cells to allogenic LPS-actiwted B cells from CBA/CaJ
mice. 20C9 mAb (100 #g/ml) was incubated with LPS-
activated B cells at 4~ for 1 h, unbound antibody was
washed away, and the LPS-blasts were fixed with parafor-
maldehyde before being used as accessory cells. Data shown
are the change in cpm, with the proliferation of the CD4
T cells in the absence of allogeneic cells subtracted. (c)
Proliferation of the Thl clone 5.9 (2 x 104/weU) to OVA
(100 #g/ml) presented by irradiated adherent cells (105/
well) from BALB/c mice. 20C9 mAb was added at a 1:2
dilution of hybridoma supernatant.
of inhibitory effects on the clonal expansion of T cells in-
duced via the TCR.
As the assay system contains both T cells and APCs, 20C9
could have inhibited T cell proliferation by binding to either
T cells or LPS-activated B cells. To resolve this issue, we in-
cubated 20C9 with LPS-activated B cells. After washing away
unbound 20C9, LPS-activated B cells were fixed with parafor-
maldehyde. As shown in Fig. 2 a, preincubation of 20C9 with
LPS-activated B cells profoundly inhibits the proliferation of
CD4 T cells induced by anti-CD3. Control experiments in-
dicate that the functional antibody cannot be eluted from
the fixed B cells because the antibody-coated cells do not in-
hibit if fixed LPS-activating B cells are added to the same
well (data not shown). The activity of 20C9 on the B cells
is consistent with two-color FACS | data, which indicate that
20C9 binds only to non-T spleen cells (Fig. 2 b). The protein
a
E
Q.
0
400000-
300000 9
200000"
100000
I
20C9
03 1 04 1 0 s 1 0 s
Accessory cells/well
k-
4 ~:"~ ~.
i ' i?--"
9 .~L ,%',~ .
~:;
~-y*~
.~ 7reatmert 0erecting mad
nil1 20~g
PI-~LC n~
----Pl-~LC 20C9
L N
log Fluorescence
10 s
o--o--o--o--o
I -- 20C9
~ Med
E
~
10 3 0 ~ 1 01 1 0 2 1 0 3
20C9 1/dilutions
Figure 2. 20C9 mAb inhibits proliferation of CD4 T cells by blocking a component on LPS-activated B cells. (a) Preincubating 20C9 mAb with
LPS-activated B cells is sufficient to inhibit the proliferation of the CD4 T cells. LPS-activated B cells were incubated with 20C9 mAb at 4~ for
1 h, unbound antibodies were washed away, and the cells were fixed with parafotmaldehyde and used as accessory cells in anti-CD3-induced proliferation
of CD4 T cells. Preincubation with normal hamster Ig or anti-CD4S mAb TIB122 has no effect on the function of the LPS-activated B cells in this
assay (data not shown). (b) Analysis of the cellular distribution of the 20(29 epitope on BALB/c ByJ spleen cells double stained with the anti-Thy-1
mAb Y19 and with 20C9. (~p) No 20C9 added;
(bottom)
20C9 present. (c) Cleavage with PI-PLC removes the 20C9 epitope from A20 cells as deter-
mined by FACScan | Similar cleavage was found in normal spleen cells (not shown). (d) 20C9 mAb inhibits the APC function of fixed LPS-activated
B cells. LPS-activated B cells were fixed with paraformaldehyde and used as accessory cells in the proliferative response of CD4 T cells from normal
CBA/CaJ mice to anti-CD3 (YCD3-1; 1:40). 20C9 mAb supernatants were added at the onset of the culture.
439 Liu et al.
on July 10, 2011jem.rupress.orgDownloaded from
Published February 1, 1992
Figure 3. Inhibition of anti-CD3 mAb-induced proliferation and cluster formation of spleen cells by various mAbs. Spleen cells (lOS/weU) from
CBA/CaJ mice were incubated with a 1:40 dilution of YCD3-1 together with either anti-LFA-1 mAb M17/5.2, anti-FcR mAb 2.4G2, or 20C9 at
various concentrations. Proliferation of the spleen cells (a) was determined at 48 h of culture. Clusters (b) were photographed at 16 h of culture in
the presence of anti-CD3 alone or with 1 /zg/ml of the inhibitory mAbs.
that this antibody recognizes is anchored to the cell mem-
brane by a GPI linkage, as PI-PLC can specifically cleave the
20C9 epitope from B cells (Fig. 2 c). Furthermore, this anti-
body strongly inhibits the accessory cell function of fixed
B cells (Fig. 2 d). As paraformaldehyde-faxed B cells are meta-
bolically inert, it is most likely that 20C9 mAb binds to and
inhibits the action of a component expressed on LPS-activated
B cells, which is necessary for proliferation of CD4 T cells.
20C9 mAb does not bind to the FcR, as it binds to FcR+
A20 cells and an FcR- variant equally well (data not
shown). In addition, 20C9 mAb does not affect the function
of the FcR. on LPS-activated B cells in anti-CD3-induced ac-
tivation of cloned T cells (Liu, Y., and C. A. Janeway, manu-
script submitted for publication). Thus, 20C9 mAb inhibits
T cell proliferation by a mechanism other than affecting the
function of the FcR.
Many mAbs specific for accessory molecules required for
T cell activation inhibit the formation of T cell APC clusters.
20C9 inhibits anti-CD3-induced proliferation of spleen cells
without inhibiting cluster formation induced by anti-CD3
mAb. This contrasts with the effects of anti-LFA-1 mAb
M17/5.2 (20) and anti-FcR mAb 2.4G2 (21), which inhibit
cluster formation as well as .proliferation. Anti-LFA-1 mAb
M17.5.2 and anti-FcR mAb 2.4G2 inhibit spleen prolifera-
440 Heat-stable Antigen Is a Costimulator of T Cell Clonal Expansion
on July 10, 2011jem.rupress.orgDownloaded from
Published February 1, 1992
E
es
o
E
r
O
10 6,
10 s . ~~ ~
20C9
10 4. --.,-,On 20C9+anti-CD3
r
r~d
J- anti-CD3
103
, ,
1'0 100 1000 10000
Responder cells
xl000
10 s] b Anti-CD3
10s]
104 1 anti-LFA-1
Anti-FoR
' ' 20C9
10311 1000
Responder
cellsxlO00
z.-
4)
,,,Q
E
r,,
(3
.I
9
' I
20C9
30C4
Medium
E
es
r
c Medium
10 6
10 s
medium
104 anti-LFA- I
anti-FcR
20C9
10 3 l i i
1 1 0 1 00 1000
Responder cellsxl000
log Fluorescence intensity
Figure 5. 20C9C7-cloned cDNA transfers 20C9 reactivity to COS cells.
COS cells at 50% confluency were transfected with 20C9C7 cDNA by
the DEAE-dextran method. The COS cell monolayer was stained with
20C9 mAb or a control hamster mAb 30C4. The cells were harvested
from the plates, and the cell surface expression of 20C9 protein was ana-
lyzed by FACScan |
Figure 4. The effect of preculture of CBA/CaJ spleen cells on subse-
quent responses to anti-CD3 plus spleen accessory cells. (a) Spleen cells
were precuhured in the presence or absence of anti-CD3 (1:40 dilution
of hybridoma supernatant) and/or 20C9 mAb (0.5/zg/ml) for 48 h. (b)
Spleen calls were treated with anti-CD3 together with 1 #g/ml of either
anti-LFA-1, anti-FcR, or 20C9 mAb. (c) Spleen cells were treated with
either no antibody or anti-LFA-1, anti-FcR, or 20C9 mAbs at 1/zg/ml
in the absence of anti-CD3 mAb. In all cases, viable cells were isolated
on lymphocyte separation medium 48 h after initial stimulation and washed
three times. These calls were then stimulated with fresh anti-CD3 mAb
and fresh irradiated CBA/CaJ spleen cells (105/we11) as APC. Prolifera-
tion of the pretreated spleen cells was determined at 72 h (a) or 48 h (b
and c) of stimulation.
tion (Fig. 3 a) as well as cluster formation (Fig. 3 b) induced
by anti-CD3 mAb; 20C9, on the other hand, inhibits anti-
CD3-induced proliferation without inhibiting duster forma-
tion. These results demonstrate that 20C9 mAb can inhibit
T cell proliferation without affecting T cell/APC adhesion.
It is worth noting that 20C9 induces a low level of duster
formation of spleen cells on its own, and that anti-CD3 mAb
further enhances this cluster formation (data not shown).
Inhibition of Costimulation by 20C9 mAb Leads to CD4 T
Cell Unresponsiveness to Subsequent Stimulation with Anti-CD3
mAb and APCs.
As stated in the introduction, stimulating
T cells with anti-CD3 in the presence of antibodies that block
costimulatory activity should lead to functional inactivation
of T ceils. By contrast, T cells treated with anti-CD3 in the
presence of mAbs that block TCR recognition should be-
have like untreated ceUs upon subsequent stimulation. This
distinction can be used to divide inhibitory antibodies into
two groups. To examine whether 20C9 blocked TCK signals
or costimulatory signals, we restimulated spleen cells recov-
ered from cultures stimulated with anti-CD3 mAb in the
presence or absence of mAbs that inhibit the proliferation
of T cells to anti-CD3 (see Fig. 3 a). As shown in Fig. 4
a, ceils that had been previously stimulated with anti-CD3
and APC mount what appears to be a secondary proliferative
response, a substantial proliferative response being seen with
very low cell numbers. The low total response may reflect
the kinetics of this response as the experiment was harvested
at the time of peak primary proliferation (day 3 of restimula-
tion). Cells treated with medium alone proliferate wdl, while
441 Liu et al.
on July 10, 2011jem.rupress.orgDownloaded from
Published February 1, 1992
cells that were pretreated with anti-CD3 in the presence of
20C9 mAb make only a marginal proliferative response re-
quiring very high cell numbers, indicating that the pretreat-
ment induces functional inactivation of the T cells. The reduc-
tion in response observed is -o20-fold relative to untreated
cells. This inactivation requires exposure to anti-CD3 in the
first culture and was not due to the carry-over of the 20C9
mAb, because treatment of the cells with 20C9 mAb in the
absence of anti-CD3 mAb allows a proliferative response in
the second culture similar to that of untreated cells. These
data suggest that engaging the TCR in the absence of 20C9
protein leads to functional inactivation of the T cells.
As seen in Fig. 3 a, mAbs directed at several different cell
surface molecules can prevent clonal expansion of CD4 T cells
induced by anti-CD3 and APCs. To test whether treatment
with mAbs that interfere with cell adhesion (anti-LFA-1) or
TCR ligation (anti-FcR) also results in functional inactiva-
tion of T cells exposed to anti-CD3, we treated spleen cells
with anti-LFA-1, anti-FcR, and 20C9 mAbs in the presence
or absence of anti-CD3 mAb. 2 d later, the antibodies were
washed away and the viable cells were restimulated with anti-
CD3 in the presence of competent APC. As shown in Fig.
4 b, cells treated with anti-LFA-1 and anti-FcR mAbs plus
anti-CD3 generate a vigorous proliferative response upon re-
stimulation, comparable with that of untreated spleen cells
(Fig. 4 c), while those pretreated with 20C9 plus anti-CD3
give a significantly reduced response. As the dose of all the
mAbs used (1 #g/ml) can almost totally inhibit the primary
proliferative response of T cells to anti-CD3 (Fig. 3 a), these
results indicate that anti-CD3 combined with anti-LFA-1 or
anti-FcR mAb does not induce functional inactivation of the
T ceils, in contrast to anti-CD3 plus 20C9 mAb, nor do we
observe the augmented response induced by anti-CD3 alone,
as seen in Fig. 4 a, in any of these cultures. The inhibition
observed with 20C9 mAb was not due to carry-over of the
mAb in the culture, as spleen cells treated with 20C9 in the
absence of the anti-CD3 mAb mount a normal proliferative
response in secondary stimulation (Fig. 4 c). Thus, the inac-
tivation observed requires both anti-CD3 and the presence
of blocking concentrations of 20C9.
Taken together, the above data indicate that 20C9 anti-
body blocks clonal expansion of T cells induced by anti-CD3,
allogeneic LPS-activated B ceils, and antigen presented by syn-
geneic spleen cells. As 20C9 does not affect ligand recogni-
tion by the TCR or cell adhesion, it is likely to block a
costimulatory signal. This conclusion is supported by the
finding that exposure of T cells to anti-CD3 in the presence
of 20C9 leads to functional inactivation of T cells.
Expression Cloning of 20C9 Antigen Reveals Its Identity with
Heat-stable Antigen,
To clone the gene encoding the 20C9
antigen, COS cells were transfected with a pCDM8-cDNA
library prepared from LPS-activated spleen B cells. Positive
q)
.Io
E
(..
m
atom
o
oh a
;~ ~ J11d
...... _
............ M1/69
NO Blocking Ab
IB B 1~
I 1~i2 103
VI,2
IO
b 2oc9
...... 20C9 ,~
NO Blocking Ab ~ I
f.., J q
/ "~
~- ; ,
,',%. , , ,,.. , , ,,1.,
rL2
Ceil Abs
CliO-FoR 0
....... CliO-FoR 20C9
.............
CHO-FcR-20C9 0
..... CHO-FcR-2OC9 20C9
9 j./,t '~
.... .... ........
F'L[
..
d A c..
,,
l: ! __
CHO-FcR Jlld
{ ! ......
CHO-FcR M1/69
" ~ i ....... CHO-FcR-20C9 Jlld
~. f [ .... CHO-FcR-20C9 M1/69
9 . / i r~
- / / i.
"- J J i
Vl_ I
log Fluorescence
Figure 6. 20C9, Jlld, and M1/69 all bind
related
epitopes.
(a) 20(29 and M1/69 block the
binding of Jlld to spleen cells. (b) M1/69 blocks
the binding of 20(29 mAb to spleen cells. (c)
Expression of 20C9 protein on CHO-FcR cells
transfected with 20C9C7 cloned cDNA. (d)
Jlld and M1/69 bind to CHO-FcR cells trans-
fected with the 20C9/C7 cDNA.
442 Heat-stable Antigen Is a Costimulator of T Cell Clonal Expansion
on July 10, 2011jem.rupress.orgDownloaded from
Published February 1, 1992
clones were enriched by four cycles of transfection followed
by panning for 20C9-positive COS cells. Plasmid DNA pre-
pared from the fourth cycle of panning was found to transfer
20C9 reactivity to COS cells. The plasmid DNA was cloned,
and of 55 clones tested, four transferred 20C9 reactivity to
COS cells. As shown in Fig. 5, COS cells transfected with
cDNA from one of those dones (20C9C7) bound 20C9 mAb
but not 30C4, a control hamster mAb. The sequence of this
cDNA clone demonstrated that it was the same as that of
the heat-stable antigen (24). Furthermore, Jlld binding to
spleen cells was inhibited by 20C9 and M1/69, while 20C9
binding to spleen cells was inhibited by M1/69 (Fig. 6, a
and b). The identity of these antigens was further confirmed
by finding that CHO cells transfected with 20C9C7 cDNA
gain reactivity with 20C9, Jlld, and M1/69 (Fig. 6, c and
d). However, mAbs Jlld and M1/69 were not effective in
inhibiting T cell proliferation to anti-CD3 mAb (data not
shown), suggesting that these mAbs differ in either their
binding sites or affinity for heat-stable antigen.
Heat-stable Antigen Can Costimulate the Clonal Expansion
ofCD4 T Cells.
We directly assessed the costimulatory poten-
tial of heat-stable antigen by transfection of 20C9C7 cDNA
into FcyRII + CHO cells (Fig. 7 a). Stable 20C9-FcRII
CHO cells were compared with untranslated FcRII-CHO
for their ability to induce proliferation of normal CD4 T
cells. As shown in Fig. 7 b, cloned 20C9-FcRII-CHO cells
induce significant proliferation of CD4 T ceils to anti-CD3,
whereas FcRII-CHO cells induce only marginal responses.
The proliferation induced by 20C9-FcRII-CHO cells was to-
tally blocked by 20C9 mAb (Fig. 7 c).
Discussion
The role of costimulators in the clonal expansion of T cells
has been defined primarily by the effect of their absence. The
lack of costimulation in T cell responses to ligand leads to
two distinct phenomena, the lack of clona] expansion and
the inactivation of T cells in forms such as clonal anergy and
induced cell death (4-6). The inactivation of T cells in the
absence of costimulation suggests that expression of costimula-
tory molecules on hemopoietic cells but not on most cells
of other tissues could be critical for self-nonself discrimina-
tion by mature T cells in the periphery (2, 4, 7, 8). Although
many molecules have been demonstrated to play a role in T
cell clonal expansion, it remains to be tested whether inacti-
vation of T cells can be achieved by stimulation in the pres-
ence of antibodies that block the activity of any of these mol-
ecules. As most of the treatments used to destroy costimulatory
activity have been nonspecific, it is possible that these two
effects are caused by the functional elimination of different
molecules. Here we report that treatment with the mAb 20C9
can inhibit clonal expansion of T cells induced by a variety
of stimuli, indicating that the protein recognized by 20C9
plays an important role in clonal expansion of T cells. Fur-
thermore, adding 20C9 to cultures of T cells stimulated by
anti-CD3 and APCs induces nonresponsiveness of T cells to
further stimulation. These results demonstrate that a single
molecule is responsible both for clonal expansion and for
prevention of clonal inactivation of T cells. Thus, the 20C9
protein fulfills the criteria for a costimulatory molecule on
APCs.
The molecules that mediate cell-cell adhesion have also been
2.
4G2
9 . no =lLbiCao-re,i)
.'t!! -- .o~:L-,'oRC:~O-,'~
= ..... no mib (clio-r~l-29
! .~ - _ ~/~ant~-1eKfCR0-/ce-20Cl
e ~
e- Q
20C9
9 9 . .o =u~(cJo-rea)
-- 20el (CHo-r=R)
..... no ~b (r
- -. 2ocl(cao-r~A.2ocgl
log Fluorescence intensity
60000'
40000"
20000-
0
10 2
FcR-CHO
i
1 03 1 04 1 ()s
150000"
100000 -
50000 -
FcR-CHO
FcR-20cg-cHo
- ~l" - FcR~I-IO +20C9
/
"-<>-:;2::
~176 /
01 - v - ";"
0 3 1 0 4 1 0 s
Number of accessory cells/well Number of CD4 T Cells/well
Figure
7. CHO cells transfeeted with 20C9 cDNA transfer costimulatory activity to FcR* CHO cells. (a) Staining of CHO-FcR and CHO-FcR-
20C9 cells with anti-FcR mAb 2.4G2
(top)
or 20C9
(bottom). (b)
Proliferation of CD4 T cells from CBA/CaJ mice to anti-CD3 mAb and CHO-FcR
or CHO-FcR-20cg. (c) 20C9 mAb (hybridoma supernatant, 1:8 dilution) inhibits proliferation of CD4 T cells to anti-CD3 stimulated by CHO-
FcR-20C9 transfectants.
443 Liu et al.
on July 10, 2011jem.rupress.orgDownloaded from
Published February 1, 1992
regarded as costimulatory molecules because antibodies that
block their function can block T cell proliferation, while trans-
fection of these molecules into fibroblasts can enhance the
T cell response to ligand. As T cells normally respond to
peptide/MHC on the surface of APCs, cell-cell contact is
a prerequisite for TCK engagement. We suggest that it is
appropriate to differentiate those molecules that are required
for ligand recognition, that is, delivery of signal one, from
costimulatory molecules that deliver signal two. Despite their
similar effects on T cell proliferation, the distinctive effects
of anti-LFA-1 and 20C9 on cluster formation and on the in-
duction of unresponsiveness clearly discriminates these two
classes of molecules.
Molecular cloning and partial DNA sequencing reveals that
the gene encoding the 20C9 protein is identical to the previ-
ously cloned gene encoding heat-stable antigen. Transfection
with cDNA encoding heat-stable antigen is sufficient to
transfer costimulatory activity to CHO cells, demonstrating
directly that heat-stable antigen costimulates T cells. It has
been documented that expression of the heat-stable antigen
is tightly controlled in immature T cells and in B cells at
different functional stages (25). The function of this mole-
cule has remained elusive. We show here that heat-stable an-
tigen cDNA from activated B cells encodes a costimulatory
molecule that can participate in clonal expansion of CD4 T
cells.
The heat-stable antigen contains a very small peptide core
with a large number of potential N-linked and O-linked
glycosylation sites. The structural basis of its costimulatory
activity is at present not understood. It is worth noting that
the level of 20C9 binding activity does not correlate directly
with the costimulatory activity of a cell. Normal B cells do
not have constitutive costimulatory activity (15), yet they bind
20C9 significantly. This discrepanc.y can be explained at least
in two ways. First, normal B cells may express an inhibitor
for the costimulatory activity of the heat-stable antigen, and
this inhibitor is inactivated during B cell activation. Second,
the heat-stable antigen may be modified during B cell activa-
tion. Since different cell types seem to have different glycosy-
lation patterns of the heat-stable antigen (24), one possibility
would be that glycosylation regulates the costimulatory ac-
tivity of the heat-stable antigen. This notion is consistent
with the earlier findings by Frohman and Cowing (26), who
showed that treatment with neuraminidase can enhance T
cell stimulation by B cells.
Adaptive immune responses by ceUs having clonally dis-
tributed receptors must discriminate self from nonsdf. Many
experiments have demonstrated that donal deletion mediated
by the interaction of immature thymocytes with antigen on
APCs is a major mechanism for removing from the mature
repertoire those T cells that recognize ligands borne by APCs
(27, 28). This mechanism, however, does not apply to an-
tigens that are expressed in tissues but are not present on
APCs in the thymus (7, 8). Thus, there must be mechanisms
to ensure self-nonsdf discrimination by mature T ceils in the
periphery. TCK engagement on mature T cells leads to a
number of different consequences depending on the costimula-
tory activity of the cells that present antigens (4-6). Self an-
tigens presented by tissue cells induce immune tolerance by
inactivating specific T cells (7, 8), whereas antigens borne
by microbes that induce costimulatory activity on APCs in-
duce potent adaptive immune responses (29, 30). Although
much data are consistent with the two-signal theory (30-32),
this hypothesis has not been subjected to a stringent ex-
perimental test because the nature of signal two on APCs
has been obscure. Hopefully, with the identification of co-
stimulatory molecules such as B7 (11-13) and heat-stable an-
tigen, the two-signal theory itself can now be directly tested.
We thank Barry Jones for A20 and its FcK variant, Ira MeUman for CHO-FcKIIB2 transfectant, Anne
Brancheau for preparation of the manuscript, and Jane Dunn for assistance in hybridoma production.
This work was supported by National Institutes of Health grant AI-26810 (to C. A. Janeway, Jr.), and
by the Bristol Myers Squibb Company. Y. Liu is a recipient of an Irvington Institute post-doctoral fellowship.
Address correspondence to Y. Liu, Division of Immunology, Department of Pathology, New York University
Medical Center, 550 First Avenue, New York, NY 10016.
Received.for publication 23 September 1991.
R~fl~rences
1. Davis, M.M., and P.J. Bjorkman. 1988. T cell antigen receptor
genes and T cell recognition.
Nature (Lond.).
334:395.
2. Lafferty, K.J., S.J. prowse, and C.J. Simeonovich. 1983. Im-
munobiology of tissue transplantation: a return to passenger
leukocyte concept.
Annu. Rev. Imraunol.
1:143.
3. Lafferty, K.J., L. Andrus, and S.J. Prowse. 1980. Role oflym-
phokine and antigen in the control of T cell responses.
Ira-
munol. Rev.
51:279.
4. MueUer, D.L., M.K. Jenkins, and K.H. Schwartz. 1989. Clonal
expansion vs. functional clonal inactivation: a costimulatory
signalling pathway determines the outcome of T cell antigen
receptor occupancy.
Annu. Rev. lraraunol.
7:445.
5. Jenkins, M.K., D.M. Pardoll, J. Mizugnchi, H. Quill, and K.H.
Schwartz. 1987. T cell unresponsiveness in vivo and in vitro:
444 Heat-stable Antigen Is a Costimulator of T Call Clonal Expansion
on July 10, 2011jem.rupress.orgDownloaded from
Published February 1, 1992
fine specificity in induction and molecular characterization of
the unresponsive state. ImmunoL Rev. 95:113.
6. Liu, Y., and C.A. Janeway, Jr. 1990. Interferon 7' plays a crit-
ical role in induced cell death of effector T cells: a possible
third mechanism of self-tolerance. J. Extx Med. 172:1735.
7. Morahan, G., J. Allison, and J.F.A.P. Miller. 1989. Tolerance
of class I histocompatibility antigens expressed extrathymically.
Nature (Lond.). 339:622.
8. Burkly, L., D. Lo, O. Kanagawa, R.L. Brinster, and R.A.
Flavell. 1989. Clonal anergy of I-E tolerant T cells in trans-
genic mice with pancreatic expression of MHC class II I-E.
Nature (Lond.). 342:562.
9. Springer, T.A. 1990. Adhesion receptors of the immune system.
Nature (Lond.). 346:425.
10. Bierer, B.E., B.P. Sleckman, S.E. Ratnofsky, and S.J. Burakoff.
1989. Biological role of CD2, CD4, and CD8 in T-cell activa-
tion. Annu. Rev. Immunol. 7:579.
11. Linsley, P.S., E.A. Clark, andJ.A. Ledbetter. 1990. The T cell
antigen, CD28, mediates adhesion with B cells by interacting
with the activation antigen B7/BB1. Proc Natl. Acad. Sci. USA.
87:5031.
12. Linsley, P.S., W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle,
and J.A. Ledbetter. 1991. Binding of the B cell activation an-
tigen B7 to CD28 costimulates T cell proliferation and inter-
leukin 2 mRNA accumulation. J. Extz Med. 173:721.
13. Koulova, L., E.A. Clark, G. Shu, and B. Dupont. 1991. The
CD28 ligand B7/BB1 provides costimulatory signal for alloac-
tivation of CD4 T cells. J. Extx Ailed. 173:759.
14. Portoles, P., J. Rojo, A. Golby, M. Bonneville, S.H. Grom-
kowski, L. Greenbaum, C.A. Janeway, Jr., D.B. Murphy, and
K. Bottomly. 1989. Monoclonal antibodies to murine CD3e
define new epitopes, one of which may interact with CD4
during T cell activation. J. Immunol. 142:4169.
15. Liu, Y., and C.A. Janeway, Jr. 1991. Microbial induction of
costimulatory activity for CD4 T cell growth. Int. lmmunol.
3:323.
16. Seed, B., and A. Aruffo. 1987. Molecular cloning of the CD2
antigen, the T cell erythrocyte receptor by rapid immunoselec-
tion procedure. Proc. Natl. A_cad. Sci. USA. 84:3365.
17. Miettinen, H., J.K. Rose, and I. Mellman. 1989. Fc receptor
isoforms exhibit distinct abilities for coated pit localization as
a result of cytoplasmic domain heterogeneity. Cell. 58:317.
18. Conrad, P., and C.A. Janeway, Jr. 1984. The expression of the
I-E d molecule in F1 hybrid mice detected with antigen-
specific, I-E d restricted cloned T cell lines. Immunogenetics.
20:311.
19. Marshak-Rothstein, A., P. Fink, T. Gridley, D.H. Raulet, M.J.
Bevan, and M.L. Gefter. 1981. Properties and application of
monoclonal antibodies directed against determinants of the
Thyl locus. J. lmmunol. 122:2491.
20. Sanchez-Madrid, F., P. Simon, S. Thompson, and T.A. Springer.
1983. Mapping of antigenic and functional epitopes on the oe
and ~ subunits of the two related mouse glycoproteins involved
in cell interaction: LFA-1 and Mac-1. J. Exl~ Med. 158:586.
21. Unkeless, J.C. 1979. Characterization of a monoclonal anti-
body directed against macrophage-lymphocyte Fc receptor. J.
Exl~ Med. 150:1152.
22. Bruce, J., F.W. Symington, T.J. McKearn, andJ. Sprent. 1981.
A monoclonal antibody discriminating between strands of T
and B cells. J. Immunol. 127:2496.
23. Springer, T., G. Galfre, D.S. Secher, and C. Milstein. 1978.
Monoclonal xenogeneic antibodies to murine cell surface an-
tigen: identification of novel differentiation antigens. Eur. J.
Immunol. 8:539.
24. Kay, R., F. Takei, and R.K. Humphries. 1990. Expression
cloning of a cDNA encoding M1/69-J11d heat-stable antigens.
J. Immunol. 145:1952.
25. Crispe, I.N., and M.J. Bevan. 1987. Expression and functional
significance of the J11d marker on mouse thymocytes. J. Im-
munol. 138:2013.
26. Frohman, M., and C. Cowing. 1985. Presentation of antigen
by B cells: functional dependence of radiation dose, interleukins,
cellular activation and differential glycosilation. J. lmmunol.
134:2269.
27. Kiesielow, P., H. Bluthmann, U.D. Staerz, M. Steinmetz, and
H. yon Boehmer. 1988. Tolerance in transgenic mice involves
deletion of nonmature CD4+CD8 + thymocytes. Nature
(Lond.). 333:742.
28. Kappler, J.W., T. Wade, J. White, E. Kushnir, M. Blackman,
J. Bill, N. Roehm, and P. Marrack. 1987. Tolerance by clonal
elimination in the thymus. Cell. 49:273.
29. Janeway, C.A., Jr. 1989. Immunogenicity: signal 1, 2, 3, and
O. Immunol. Today. 10:283.
30. Janeway, C.A., Jr. 1989. Approaching the asymptote? Evolu-
tion and revolution in immunology. Cold Spring Harbor Syml~
Quant. Biol. 54:1.
31. Bretscher, P.A., and M. Cohn. 1970. The theory of self non-
self discrimination. Science (Wash. DC). 169:1042.
32. Schwartz, R.H. 1989. Acquisition of immunological self-
tolerance. Cell. 57:1073.
445 Liu et al.
on July 10, 2011jem.rupress.orgDownloaded from
Published February 1, 1992
... A significant decrease in the number of circulating B cells can also be caused by the anti-CD24 mAb by killing growing B cells. Additionally, anti-CD24 mAb stops T cells from being costimulated to further promote immunosuppression [66,67]. ...
Article
Full-text available
The small, heavily glycosylated protein CD24 is primarily expressed by many immune cells and is highly expressed mostly in cancer cells. As one of the most crucial biomarkers of cancers, CD24 is frequently highly expressed in solid tumors, while tumor-associated macrophages express Siglec-10 at high levels, Siglec-10 and CD24 can interact on innate immune cells to lessen inflammatory responses to a variety of disorders. Inhibiting inflammation brought on by SHP-1 and/or SHP-2 phosphatases as well as cell phagocytosis by macrophages, the binding of CD24 to Siglec-10 can prevent toll-like receptor-mediated inflammation. Targeted immunotherapy with immune checkpoint inhibitors (ICI) has lately gained popularity as one of the best ways to treat different tumors. CD24 is a prominent innate immune checkpoint that may be a useful target for cancer immunotherapy. In recent years, numerous CD24/Siglec-10-related research studies have made tremendous progress. This study discusses the characteristics and workings of CD24/Siglec-10-targeted immunotherapy and offers a summary of current advances in CD24/Siglec-10-related immunotherapy research for cancer. We then suggested potential directions for CD24-targeted immunotherapy, basing our speculation mostly on the results of recent preclinical and clinical trials.
... Many other receptor-ligand pairs have also been implicated in provided costimulatory signals to T cells. These include (receptor/ligand): LFA-1/ICAM-1 3 (3-7), CD2/CD48 (CD58) (8 -11), CD44/invariant chain-chondroitin sulfate (12), unknown/VAM-1 (13), unknown/heat-stable Ag (14), unknown/ CD43 (15,16), and TNFR/TNF family members such as CD70/ CD27 (17,18), CD40L/CD40 (19), 4-1BB/4-1BBL (20,21), OX-40/OX-40L (22), and CD30/CD30L (23). However, none of these molecules induces all of the functions associated with CD28 signaling; each has some restriction either on the population of T cells that respond or on the specific activation events that can be induced. ...
Article
LFA-1 is a well-recognized adhesion molecule, but its role in providing costimulatory signals to T cells has remained controversial. We have compared the ability of class II-positive transfectants that do and do not coexpress ICAM-1 (ProAd and ProAd-ICAM) to activate Ag-specific Th1 clones and naive CD4-positive T cells isolated from TCR transgenic mice. Ag presentation by ProAd to Th1 clones can induce calcium-dependent signaling events after engagement of the TCR, as evidenced by the nuclear localization of the transcription factors NF-AT and NF-κB. Nevertheless, coexpression of ICAM-1 or B7-1 on ProAd is required to induce detectable levels of IL-2 gene expression in either Th1 clones or naive T cells. In Th1 clones, activation by ProAd-ICAM induces very transient IL-2 mRNA expression that does not result in detectable IL-2 secretion or T cell proliferation. In naive T cells, the duration of IL-2 mRNA expression is longer, allowing for a transient burst of IL-2 protein that is sufficient to drive the cells into the cell cycle. In spite of this initial response, Ag presentation by ProAd-ICAM is a tolerogenic signal to naive T cells, and responding T cells undergo apoptosis 4 to 5 days poststimulation. These data suggest that engagement of LFA-1 can provide sufficient costimulatory signals to induce T cell activation and IL-2 gene expression, but cannot protect against anergy induction or provide for T cell survival.
... A variety of studies have revealed that CD24 plays a role in regulating the functions of anti-gen presenting cells (APC). For instance, CD24 on APC has been shown to mediate CD28 independent co-stimulation of CD4 and CD8 T cells [4,[12][13][14][15][16]. CD24 expression on DC has been shown to control the rapid homeostatic proliferation of syngenic T cells in a lymphopenic model [17]. ...
Article
CD24 is a glycosyl-phosphatidylinositol (GPI) anchored cell surface glycoprotein with a variety of immunomodulatory functions such as inhibition of thymic generation of autoreactive T cells, regulation of antigen presenting cell functions, and mediation of autoimmunity. Given the autoimmune nature of FoxP3+ regulatory T cells and their importance in autoimmune diseases, we hypothesize that CD24 regulates the generation and functions of Treg cells. Through the analysis of the Treg repertoire in two strains of CD24-deficient mice, we found that CD24 does not globally affect the thymic generation of Treg cells. However, CD24 is abundantly expressed on Treg cells, and CD24 antibody treatment of Treg cells enhances their suppressive functions. Concurrently, we observed CD24-deficient Treg cells exhibit increased suppressive functions and produce more IL-10 compared to their wild type counterparts. In addition, CD24-deficient Treg cells exhibited more potent suppressive capacity in inhibiting the development of experimental autoimmune encephalomyelitis (EAE) in mice. Thus, CD24 on Treg cells regulates their suppressive functions. Our findings can partially explain the resistance of EAE development in CD24-deficient mice and CD24 polymorphism-associated susceptibility of human autoimmune diseases. Further investigations regarding mechanisms of CD24 regulation of Treg function may lead to a new approach for the immunotherapy of human autoimmune diseases.
... It was initially shown that mouse CD24 on antigen presenting cells can act as a CD28-independent costimulatory molecule for both CD4 and CD8-T cell responses. [129][130][131][132] Furthermore, CD24 on T cells was found to be essential for T cell homeostatic proliferation. 133 Considering the various possible binding partners (see Table 1 Phagocytosis is an important mechanism that allows the innate immune system to clear the body of dangerous or toxic substances. ...
Article
Full-text available
CD24 is a highly glycosylated protein with a small protein core that is linked to the plasma membrane via a glycosyl‐phosphatidylinositol anchor. CD24 is primarily expressed by immune cells but is often overexpressed in human tumors. In cancer, CD24 is a regulator of cell migration, invasion and proliferation. Its expression is associated with poor prognosis and it is used as cancer stemness marker. Recently, CD24 on tumor cells was identified as a phagocytic inhibitor (“do not eat me” signal) having a suppressive role in tumor immunity via binding to Siglec‐10 on macrophages. This finding is reminiscent of the demonstration that soluble CD24‐Fc can dampen the immune system in autoimmune disease. In the present review, we summarize recent progress on the role of the CD24‐Siglec‐10 binding axis at the interface between tumor cells and the immune system, and the role of CD24 genetic polymorphisms in cancer. We describe the specific function of cytoplasmic CD24 and discuss the presence of CD24 on tumor‐released extracellular vesicles. Finally, we evaluate the potential of CD24‐based immunotherapy.
Article
Full-text available
CD24 has emerged as a molecule of significant interest beyond the oncological arena. Recent studies have unveiled its surprising and diverse roles in various biological processes and diseases. This review encapsulates the expanding spectrum of CD24 functions, delving into its involvement in immune regulation, cancer immune microenvironment, and its potential as a therapeutic target in autoimmune diseases and beyond. The ‘magic’ of CD24, once solely attributed to cancer, now inspires a new paradigm in understanding its multifunctionality in human health and disease, offering exciting prospects for medical advancements.
Article
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as it utilizes patients’ own immune systems in combating the cancer cells. Cancer cells escape immune surveillance by hijacking the corresponding inhibitory pathways via overexpressing checkpoint genes. Phagocytosis checkpoints, such as CD47, CD24, MHC-I, PD-L1, STC-1 and GD2, have emerged as essential checkpoints for cancer immunotherapy by functioning as “don’t eat me” signals or interacting with “eat me” signals to suppress immune responses. Phagocytosis checkpoints link innate immunity and adaptive immunity in cancer immunotherapy. Genetic ablation of these phagocytosis checkpoints, as well as blockade of their signaling pathways, robustly augments phagocytosis and reduces tumor size. Among all phagocytosis checkpoints, CD47 is the most thoroughly studied and has emerged as a rising star among targets for cancer treatment. CD47-targeting antibodies and inhibitors have been investigated in various preclinical and clinical trials. However, anemia and thrombocytopenia appear to be formidable challenges since CD47 is ubiquitously expressed on erythrocytes. Here, we review the reported phagocytosis checkpoints by discussing their mechanisms and functions in cancer immunotherapy, highlight clinical progress in targeting these checkpoints and discuss challenges and potential solutions to smooth the way for combination immunotherapeutic strategies that involve both innate and adaptive immune responses.
Article
We have previously demonstrated that the inhibitory effects of IL-10 on ConA-induced T cell proliferation or IL-2 production by resting murine T cells were only observed when macrophages, but not when activated B cells, dendritic cells, or L cells, were used as accessory cells. To further elucidate the mechanism of action of IL-10 on the inhibition of macrophage costimulatory activity, we have used a system in which macrophages can develop into effective costimulator cells and the effect of IL-10 on this process can be studied in the absence of T cells. After fixation, resting macrophages have no costimulatory activity for soluble anti-CD3-induced T cell proliferation nor do they express the activation Ag B7/BB1. In contrast, macrophages activated by culture alone, or by culture with IFN gamma or LPS for 24 h, and then fixed, were effective accessory cells, expressed B7, and their costimulatory activity correlated with their level of cell surface B7 expression. Addition of IL-10 during the process of macrophage activation resulted in both a marked reduction in costimulatory activity and in B7 expression. IL-4 and transforming growth factor-beta that suppress many macrophage functions did not inhibit the induction of B7 expression. The inhibitory effect of IL-10 on the up-regulation of B7 was selective because the up-regulation of intercellular adhesion molecule-1 and MHC class II Ag was not affected. Direct evidence that the lack of B7 is the relevant limiting defect for IL-10-treated macrophage accessory cell function was obtained from studies in which the costimulatory capacity of IL-10-treated macrophages could be completely restored by the addition of B7 transfected, but not nontransfected, L cells to the assays.
Article
Full-text available
Objective: Studies have shown that cluster of differentiation (CD) 24 gene polymorphism is associated with several diseases. Among these, chronic hepatitis B (CHB) infection has not been investigated. This study aimed to assess the function of CD24 in CHB. Methods: The study included 478 cases of CHB and 318 cases without CHB from 230 families that underwent genotyping. Polymerase chain reaction-restriction fragment length polymorphism was performed to assess the single nucleotide polymorphism (SNP) P170 of the CD24 gene. The detected genotypes were TT, CT, and CC. Then, family based-association analysis was carried out to investigate the association between CD24 gene polymorphism and susceptibility to CHB. Results: In the 478 patients with CHB, the frequencies of CD24 P170 T and C alleles were 35.5% and 64.5%, respectively, and the frequencies of CD24 P170 CC, CT, and TT genotypes were 39.3%, 50.4% and 10.3%, respectively. In a CD24 single-locus analysis by a family-based association test of P170 polymorphisms, T and C were not significantly associated with CHB in the additive (Z = 0.169, P = 0.866; Z = -0.169, P = 0.866, respectively), dominant (Z = 0.522, P = 0.602; Z = 0.428, P = 0.669, respectively), or recessive (Z = -0.428, P = 0.669; Z = -0.522, P = 0.602, respectively) models. Transmission-disequilibrium (TD) and sib-transmission disequilibrium (STD) tests revealed no excess of T or C alleles from heterozygous parents to their children with the disease or higher frequencies of these alleles in patients compared with their normal siblings (χ 2 = 0.06, P = 0.897). Conclusion: The study findings suggest that the SNP P170 of CD24 has no significant association with susceptibility to the HB virus and related phenotypes in Chinese patients.
Thesis
The role of indirect T cell allorecognition in transplantation has been investigated. Peptides from the alpha helical regions of class I MHC have been used in a rat kidney graft model to study the effect of priming to indirect T cell allorecognition on the efficacy of cyclosporin A immunosuppresion. The work in this thesis demonstrates that priming with peptide to indirect T cell allorecognition does not influence graft function or survival under cyclosporin A therapy. However cyclosporin A could not suppress the early antibody response seen to the grafts in the primed rats. Multiple blood transfusions given prior to grafting can lead to a prolongation of graft survival. To try to elucidate the mechanisms of this process LEW recipients were primed to indirect T cell allorecognition by immunisation with a DA class I peptide before or during multiple blood transfusions. These peptide immunisation studies suggest that multiple blood transfusion suppresses the T helper pathway The other main area of interest has been the study of the mechanisms of xenograft rejection, where indirect recognition could play a major role in the rejection process. In this thesis I have used various strategies to induce prolongation of survival of the concordant mouse-to-rat vascularised heterotopic heart graft model. Therapies including cyclosporin A, CTLA4-Ig and splenectomy were used. The rejection response between these closely related species was very vigorous. Marked prolongation of survival was seen when all three of the therapies were combined. Most of the recipients did not reject their grafts whilst under treatment. Interestingly nude rats also rejected their grafts in a similar time span to controls. Pathology of the grafts at the time of rejection indicated a mild infiltrate that was negative for T cell markers and contained polymorphonuclear cells. Rat antibodies to mice were detected at day 3 (the day of rejection), indicating a humoral rejection response. Recipients with grafts that survived past day 18 post transplant demonstrated a massive cellular infilitration of the graft at the time of rejection and no rat anti-mouse antibodies. These studies suggest that once the initial antibody-mediated phase has been overcome, cellular mechanisms might play a dominant role in the rejection response of these vascularised concordant cardiac xenografts.
Article
Full-text available
To investigate the antigenic relationship between the macrophage and lymphocyte Fc receptors (FcR), a monoclonal antibody capable of blocking mouse macrophage Fc receptors was selected. Hybrids were formed by fusing the P3U1 mouse myeloma and spleen cells from a rat immunized with the mouse macrophage-like cell lines J774 and P388D1. The Fab fragment of the monoclonal IgG secreted by clone 2.4G2, inhibited the trypsin-resistant Fc receptor II (FcRII), which is specific for immune aggregates of mouse IgG1 and IgG2b, but had no inhibitory effect on the trypsin-sensitive Fc receptor I (FcRI), which binds monomeric IgG2a and erythrocytes coated with IgG2a. Thus, the monoclonal 2.4G2 IgG appeared to be specific for macrophage FcRII. Further evidence that the 2.4G2 IgG was directed against FcRII came from binding studies of the monoclonal antibody to J774 cells and a series of independently isolated variants which do not express FcRII. These variants of J774 bound 5% as much of the monoclonal antibody as the parent line, which bound 600,000 molecules of 2.4G2 IgG per cell. The antigenic relatedness of mouse lymphocyte FcR to mouse macrophage FcRII was demonstrated by the binding of 2.4G2 IgG to FcR-bearing lymphoid cell lines and the inhibition of the lymphocyte FcR by the monoclonal antibody. Preincubation of spleen cells and peritioneal cells with 2.3G2 IgG likewise inhibited rosette formation with ox erythrocytes coated with rabbit IgG. The ability of the hybridoma IgG to inhibit mouse FcRII was independent of the major histocompatibility complex. The 2.4G2 IgG antigenic determinant was not present on rat, guinea pig, rabbit, or human FcR-bearing cells.
Article
Full-text available
Activation via the T lymphocyte cell surface molecule CD28 provides a potent amplification signal for interleukin 2 (IL-2) production in several in vitro systems. The B lymphocyte activation antigen, B7/BB1, is a natural ligand for CD28. Here we investigate the role of CD28 and B7/BB1 in primary activation of CD4+ T lymphocytes stimulated with allogeneic B lymphoblastoid cell lines. A subset of peripheral CD4+ T cells that is unresponsive to crosslinking of CD3/T cell receptor (TCR) with CD3 monoclonal antibody (mAb) does proliferate in response to allogeneic B lymphoblasts. TCR binding to allogeneic major histocompatibility complex antigens was an absolute requirement for activation of these cells because mAbs to either CD3 or human histocompatibility leukocyte antigen (HLA) class II completely inhibited activation. CD28 and B7/BB1 antibodies inhibited T cell proliferation 90% and 84%, respectively. Similar results were obtained with the total CD4+ T lymphocyte population. Crosslinking of HLA-DR antigens on small, resting B cells induced rapid expression of B7/BB1, which peaked at 6 h and returned to baseline levels within 18 h. These data demonstrate that CD28-B7/BB1 binding provides an important early second signal for alloactivation of CD4+ T lymphocyte by B lymphoblasts. The results also suggest that T cells interacting with allogeneic resting B cells may induce B7/BB1 expression in the alloantigen-presenting cell as a consequence of interaction between the TCR and class II molecules.
Article
Full-text available
A successful immune response requires intercellular contact between T and B lymphocytes. We recently showed that CD28, a T cell surface protein that regulates an activation pathway, could mediate intercellular adhesion with activated B cells by interaction with the B7 antigen. Here we show that CD28 is the primary receptor for B7 on activated peripheral blood T cells, that CD28 binds to B7 in the absence of other accessory molecules, and that interaction between CD28 and B7 is costimulatory for T cell activation. To characterize the binding of CD28 to B7, we have produced genetic fusions of the extracellular portions of B7 and CD28, and immunoglobulin (Ig) C gamma 1 chains. 125I-labeled B7 Ig bound to CD28-transfected Chinese hamster ovary (CHO) cells, and to immobilized CD28 Ig with a Kd approximately 200 nM. B7 Ig also inhibited CD28-mediated cellular adhesion. The function of CD28-B7 interactions during T cell activation was investigated with soluble fusion proteins and with B7-transfected CHO cells. Immobilized B7 Ig and B7+ CHO cells costimulated T cell proliferation. Stimulation of T cells with B7+ CHO cells also specifically increased levels of interleukin 2 transcripts. These results demonstrate that the CD28 signaling pathway could be activated by B7, resulting in increased T cell cytokine production and T cell proliferation. Cellular interactions mediated by B7 and CD28 may represent an important component of the functional interactions between T and B lymphoid cells.
Article
Full-text available
We have used anti-T cell monoclonal antibodies (mAbs) as mimic ligands to study the effects of T cell receptor (TCR) ligation of cloned T helper type 1 cells in the presence or absence of accessory cells. Our results demonstrate that ligation of the TCR in the absence of accessory cells rapidly induces cell death. Cell death can be prevented by addition of spleen adherent cells, leading to strong clonal expansion. Induced cell death is inhibited by cyclosporin A and by anti-interferon gamma (IFN-gamma), and is restored by adding exogenous recombinant IFN-gamma to cyclosporin A-treated cells. These results demonstrate that IFN-gamma plays a critical role in cell death induced by anti-TCR mAbs in the absence of costimulatory cells. We propose that induced cell death of active effector T cells provides a third mechanism of tolerance in addition to intrathymic deletion of developing autoreactive T cells and peripheral inactivation of mature, naive T cells.
Article
The most critical property of the immune system is its ability to discriminate self from nonself. Failure to respond to nonself can lead to overwhelming infection, while failure in the ability not to respond to self, or self tolerance, leads to autoimmunity. A meeting held in Steamboat Springs focused on this issue under the title of ‘Immunogenicity’. This brief summary focuses on one of the key issues considered at this conference — the signals involved in the induction of lymphocyte activation. In addition, an hypothesis of immune system function that appears to follow from these findings is described.
Article
Hybrid myeloma cell lines secreting monoclonal antibodies to mouse cell surface antigens have been prepared. Spleen cells from a DA rat immunized with B10 mouse spleen cells that had been enriched for T cells were fused to cells from a nonsecreting mouse myeloma line (NSI). The presence in the culture supernatants of antibodies binding to mouse spleen cells was tested by a binding assay with ¹²⁵ I‐labeled anti‐rat IgG. From a large number of positive cultures, ten independent hybrid clones were purified, each secreting a different antibody. Each antigenic target was analyzed by (a) gel electrophoresis of immunoprecipitated ¹²⁵ I‐labeled cell surface molecules, (b) heat stability, (c) strain and species distribution and (d) cross‐inhibition of binding of different monoclonal antibodies. It was concluded that the ten monoclonal antibodies regognized four types of antigen. One was the heterophile, heat‐stable, Forssman antigen. The second (mol.wt. 210 000) appears to be a major ¹²⁵ I‐labeled lymphoid cell surface protein. The third, a minor component of spleen cells, was precipitated as two polypeptides of mol.wt. 190 000 and 105000. Five IgG‐secreting clones identify the fourth antigen, a heat‐stable, possibly glycolipid component expressed on mouse red blood cells and also on thymocytes. Cross‐inhibition studies suggest that these last monoclonal antibodies bind to overlapping, but not identical, determinants. The class and chain composition of the monoclonal antibodies were studied by gel electrophoresis, isoelectric focusing and ability to lyse red blood cells and thymocytes.
Article
Fusion of cells of the mouse myeloma line, P3/X63-Ag8 with spleen cells from AKR/J mice immunized against C3H thymocytes or from (BALB/c x BALB.K)F1 mice immunized against AKR/J thymocytes gave rise to hybrid cell lines that continuously secrete antibodies specific for the Thy-1.2 and Thy-1.1 antigens, respectively. Monoclonal antibodies from four such cell lines were analyzed in detail. All were 19S IgM, and, in the presence of complement (C), had high lytic titers on T cells of the appropriate antigenicity. Their specificity was shown by lysis of thymocytes from Thy-1 congenic mouse strains, A/J(Thy-1.2) and A. Thy 1.1. Furthermore, they lyse only 60 to 70% of lymph node cells, suggesting cytotoxicity for mature T cells and not B cells. Treatment of peripheral lymphocyte populations with monoclonal antibody plus C eliminated effector cytotoxic T lymphocytes, their precursors, and the mitogenic response to Con A, but did not affect the response to LPS. Purified, fluorescein-labeled monoclonal anti-Thy-1 antibody could be used to distinguish T and B cells. Purified antibody coupled to Sepharose 6MB was used to separate viable T and B cells. Two independently isolated anti-Thy-1.2 hybridomas are indistinguishable and bind the same determinant whereas a third is unique and may bind a separate site.
Article
The activation of naive CD4 T cells by antigen is a critical step in the initiation of an immune response; it requires both ligation of the T-cell receptor (TCR) and the delivery of co-stimulatory factors by accessory cells. We have examined the role of syngeneic accessory cells in the response of purified normal CD4 T cells to anti-CD3 antibody as ligand. We show that the ability to deliver co-stimulatory signals is inducible in B cells by microbial products such as bacterial lipopolysaccharide (LPS), mitogenic influenza viruses, and synthetic polyinosinic-polycytidylic acid (poly-I:C) as a mimic of viral infection. LPS stimulation for 16 h allows the co-stimulatory activity of B cells to become resistant to paraformaldehyde fixation. LPS induction of fixation-resistant co-stimulator activity requires new protein synthesis, as it is inhibited by cycloheximide. Using the anti-CD45RB mAb 16A as marker for naive and memory CD4 T cells, we show that B cells activated by LPS and by poly-I:C can provide co-stimulatory signal to both naive and memory CD4 T cells. By contrast, zymosan particles, which are known to activate macrophages in a variety of assays, do not activate B cells to become co-stimulatory, but do induce this activity in macrophages. These data demonstrate that a variety of infectious agents or their constituents can induce accessory cells to become co-stimulatory for CD4 T cells. They are interpreted in light of a proposed role for two classes of recognition in the induction of the immune responses, specific recognition of antigens and non-specific recognition of infectious agents. These data support the contention that the immune system uses this mechanism to discriminate infectious non-self from non-infectious self.
Article
The adhesive interactions of cells with other cells and with the extracellular matrix are crucial to all developmental processes, but have a central role in the functions of the immune system throughout life. Three families of cell-surface molecules regulate the migration of lymphocytes and the interactions of activated cells during immune responses.
Article
The differentiation Ag identified by the mAb M1/69 and J11d (commonly referred to as heat-stable Ag) are found in structurally heterogeneous forms on the surfaces of many types of murine hemopoietic cells. The extinction of expression of these antigens is associated with thymocyte maturation and Ig class switching in B cells, as well as terminal differentiation of macrophages. A cDNA encoding the M1/69-J11d peptide was cloned from a hemopoietic progenitor cell line by immunoselection of COS cells transfected with expression libraries. The cloned cDNA is a copy of a gene that is transcribed in M1/69-J11d+ lymphoid, myeloid, and erythroid cells. This gene could be responsible for the expression of all forms of the M1/69-J11d Ag, although there are homologous genes that may encode some forms of the Ag that are specifically expressed in bone marrow. The cloned cDNA encodes a surprisingly small peptide, predicted to contain only 30 amino acids after removal of a signal sequence and displacement of the C-terminal region by the glycosyl-phosphatidylinositol group that anchors the peptide to the cell surface. Almost all of the mass of the M1/69-J11d Ag accumulates through extensive N- and O-linked glycosylation at multiple sites in the short peptide. These carbohydrates are likely to execute the functions of M1/69-J11d Ag, which could be specialized to each cell type as a consequence of differential glycosylation.